IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.67▼ 0.02% USD/MXN18.57▲ 0.30% USD/CLP994.16▼ 0.13% USD/COP 3,303 — 0.00% USD/PEN3.41▲ 0.17% USD/ARS1,544▼ 0.02% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB11.59— 0.00% USD/DOP 60.59 — 0.00% USD/CRC 442.74 — 0.00% USD/GTQ 7.64 — 0.00% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES911.74▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69— 0.00% USD/TTD6.75— 0.00% EUR/BRL6.25▼ 0.04% BRENT 92.71 ▼ 3.27% WTI 88.47 ▼ 0.10% IRON ORE 161.91 — — COPPER 6.02 ▼ 0.90% GOLD 3,857 ▼ 0.75% SILVER 47.26 ▼ 3.62% SOY 1,228 ▼ 1.21% CORN 445.00 ▼ 0.11% WHEAT 591.00 ▼ 0.38% COFFEE 279.10 ▲ 0.16% SUGAR 18.30 ▼ 0.60% ORANGE JUICE 136.85 ▼ 2.91% COTTON 81.40 ▲ 3.33% COCOA 5,145 ▲ 0.51% BEEF 220.65 ▲ 0.80% CATTLE 339.03 ▲ 1.00% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00% IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.67 ▼ 0.02% USD/MXN 18.58 ▲ 0.38% USD/CLP 994.16 ▼ 0.13% USD/COP 3,303 — 0.00% USD/PEN 3.41 ▲ 0.17% USD/ARS 1,544 ▼ 0.02% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB 11.59 ▲ 2.15% USD/DOP 60.59 — 0.00% USD/CRC 442.74 — 0.00% USD/GTQ 7.64 — 0.00% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES 911.74 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.75% USD/TTD 6.75 ▲ 2.58% EUR/BRL 6.25 ▼ 0.04% BRENT 92.71 ▼ 3.27% WTI 88.47 ▼ 0.10% IRON ORE 161.91 — — COPPER 6.02 ▼ 0.90% GOLD 3,857 ▼ 0.75% SILVER 47.26 ▼ 3.62% SOY 1,228 ▼ 1.21% CORN 445.00 ▼ 0.11% WHEAT 591.00 ▼ 0.38% COFFEE 279.10 ▲ 0.16% SUGAR 18.30 ▼ 0.60% ORANGE JUICE 136.85 ▼ 2.91% COTTON 81.40 ▲ 3.33% COCOA 5,145 ▲ 0.51% BEEF 220.65 ▲ 0.80% CATTLE 339.03 ▲ 1.00% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00%
since 2009
Monday, November 16, 2026

Brazil Covid-19

Brazil approves clinical trial for first Covid-19 vaccine developed in the country

By · · 2 min read

Brazilian health authorities on Monday approved a clinical trial for the first Covid-19 vaccine developed in the country, officials said.

The National Health Inspectorate (Anvisa) announced Monday that it had approved a clinical trial of SpiN-Tec.

SpiN-Tec is a recombinant chimeric protein developed by the Center for Vaccine Research and Production at the Federal University of Minas Gerais in southeastern Brazil.

Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.
Brazil approves clinical trial for first Covid-19 vaccine developed in the country.
Brazil approves clinical trial for first Covid-19 vaccine developed in the country.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

For approval, Anvisa analyzed data from earlier phases, including nonclinical in vitro and animal studies, and preliminary data from clinical trials. Results to date have shown an acceptable safety profile for the vaccine candidate.

According to Anvisa, the SpiN-Tec trial is conducted in humans for the first time and consists of two phases.

One is “a Phase 1 dose-escalation clinical trial to evaluate the safety and reactogenicity of the investigational product, and the other is to evaluate the safety and immunogenicity of SpiN-Tec.”

In addition, the clinical trial will include healthy participants of both sexes, aged 18-85 years, who have completed initial vaccination with Coronavac or Covishield (Astrazeneca/Oxford) and who have received one or two booster doses of Covishield or Comirnaty (Pfizer) for at least six months, Anvisa said.

The Federal University of Minas Gerais funds the study, the Ministry of Science, Technology, and Innovation (MCTI), the Oswaldo Cruz Foundation (Fiocruz), and the City of Belo Horizonte, the regional capital of Minas Gerais, Brazil.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.